CHANCE-2 clinical trial including individuals mainly carriers of the CYP2C19 loss-of-function alleles, ticagrelor and aspirin was superior to clopidogrel and aspirin in reducing the risk of subsequent stroke and did not increase the risk of severe or moderate bleeding. The gene discussed is CYP2C19; the disease is stroke disorder.